7mer-1A 7mer-m8 7mer-m8 Log2 median-centered intensity Non-TNBC (n=129) TNBC (n=39)
P=9. 77E-6 Bittner Breast (GSE 2109)
Non-TNBC (n=1340) TNBC (n=211) P=3 . 12E-27 Curtis Breast (EGAS00000000083) Ras2UTR-mut7
shRasal2-2-B
5'-aattcACGCGTAAAAAAGCAGGACAGTTCAACCTAATATCTCTTGAATATTAGGTTGAACTGTCCTGCg-----3'
Real time primers
5′-AGGATAAAGAGCTTAGAACAGCGAA-3′
Supplemental Method

Survival analysis and molecular subtype association analysis
Meta-analysis of patient overall survival (OS) and distant metastasis free survival mixed with relapse free survival (DMFS & RFS) on a total of 10 breast cancer cohorts (Chin breast, GSE11121, GSE12093, GSE1456, GSE2034, GSE2603, GSE3494, GSE5327, GSE6532 and GSE7390) comprising 1789 patients were performed using the intrinsic settings of the GOBO algorithm after normalization cross cohorts and platforms (http://co.bmc.lu.se/gobo/) (1).
Patients were divided into three groups based on low (0-33%), intermediate ( For the peptide blocking experiment, the same procedure was adapted except that the antibody was incubated with an epitope peptide (provided by the same company PrEST
Antigen for Anti-RASAL2 NBP1-82579 (HPA018805) at antibody: peptide ratio 1:2 for 30 minutes at room temperature prior to exposure to TMA slides.
Mouse pulmonary metastasis models and bioluminescence measurement Comparisons of primary tumour and BLI lung metastasis growth between groups were performed using two tailed student t-test analysis. Animal survival curve was generated using Kaplan-Meier analysis and the statistical parameters were calculated by Log-Rank (mantel-Cox) test using Graphpad Prism software as described previously (3).
RNA isolation and Q-RT-PCR
Snap frozen human breast cancer tissues were disrupted using TissueLyser II (Qiagen). Total RNA including small RNAs from both human breast cancer tissue as well as the cell lines were isolated using miRNeasy Mini Kit (Qiagen, cat. 217004) according manual. FFPE sample RNAs were extracted using Qiagen All Prep DNA/RNA FFPE Kit (Cat. No. 80234).
Agilent Human miRNA Microarray Kit V3 (G4470C) which contains probes for 866 human from the Sanger database v12.0 was utilized in profiling the miRNA expression in cell lines as described previously (4) . In brief, 100 ng total RNA was dephosphorylated with calf intestine alkaline phosphatase, denatured with dimethyl sulfoxide and labeled with pCp-Cy3 using T4 RNA ligase. The labeled RNAs were hybridized to Agilent human miRNA microarray slides for 22 hours. After extensive washing, the arrays were scanned with Agilent microarray scanner and the raw intensity data were further analyzed using GeneSpring GX software (Agilent Technologies, Santa Clara, CA). Differentially expressed miRNAs were analyzed by significant analysis of microarray (SAM) protocol. To quantify mature form miRNA expression levels in patient samples the TaqMan MicroRNA assays were utilized following the manufacturer's protocol (Thermo Scientific, Waltham, MA).
RNU6B levels were used to normalize the data. To quantify protein coding gene mRNA expression levels the KAPA SYBR® FAST qPCR Kits (KAPA Biosystems, Wilmington, MA) were applied following c-DNA conversion using High Capacity cDNA Archive kits (Applied Biosystems). For normalization purpose 18S level was used as internal control. All Q-RT PCR reactions were analyzed in an ABI 7500HT Fast Real-Time PCR system in 96-well plate format. Q-PCR Primer sequences can be found in Supplemental Table 2 . 
Plasmids construction
RASAL2 (NM_170692.2), ARHGAP24 (NM_001025616.
Cell viability assay
Cell viability was determined using CellTiter-Glo™ Luminescent Cell Viability Assay kit 
Transwell invasion assay
Transwell invasion assay were performed using 24-well FluoroBlok transwell insert (Falcon, Dallas, TX) with a pore size of 8 µm according to manufacturer suggested protocol. In brief the inserts were pre-coated with growth factor-reduced Matrigel (BD Biosciences, cat:
354230 Falcon) for 6 hrs at 37˚C at the concentration of 600 µg/ml for the mesenchymal like TNBC cell lines MB231-LN or BT-549 and 200 µg/ml for the non-mesenchymal like TNBC cell lines HCC1806 or HCC1937 respectively. Then 5x10 4 of cells were seeded into each insert in MEM containing 0.25% FBS as serum starvation medium. The insert were subsequently immersed in DMEM medium supplemented with 10% FBS as a chemoattractant in the outer chamber. Invaded cells were fixed after 48 hours of incubation by using 3.7 % formaldehyde and stained with 5 µg/ml propidium iodide (Sigma-Aldrich).
The invaded cells were scanned and counted with CELLOMICS ARRAYSCAN® VTI HCS Reader facility (Thermo Scientific) using standard settings.
Wound Healing Migration Assays
Equal number of indicated MB231-LN cells and sublines were seeded on BioCoat™ collagen I coated 6-well tissue culture dishes (BD Biosciences, cat: 354400) and allowed to grow to confluent after 48 hours. Then scratches were made using p200 pipette tips and floated cells were carefully washed away with fresh growth medium. The wound-healing of the scratch regions were monitored and imaged at designated time points (0, 4, 6, and 8 hours respectively).
Three dimensional Matrigel growth assays
The 8-well chamber slides (Falcon, cat: 354656, Falcon) were pre-coated with 7.6 mg/ml growth factor-reduced Matrigel (Falcon, cat: 354230, Falcon) for 30 min at 37˚C.
Approximately 5x10 3 MB231 and BT-549 with indicated treatments were seeded in each well in DMEM medium containing 10% FBS and 150 µg/ml Matrigel. Medium were replenished every 3 days and cell growth was monitored every 3 days by imaging.
Tumorsphere assay
Active growing MB231-LN and BT-549 cells were treated with 0.05% trypsin for 10 minutes then passed through 0.4 µm cell strainer to achieve single cell suspension. Approximately 1x10 4 cells were re-suspended in 2 ml of MammoCult medium supplemented with 0.5µg/ml hydrocortisone and 4µg/ml heparin (STEMCELL Technologies, Vancouver, BC, cat: 05621).
After washing the cells were seeded in 6-well ultra-low attachment plates (Corning, Corning, NY, cat: CLS3471). Tumor spheres formation was monitored daily up to day 7 until being stained with 4 μg/ml p-Iodonitrotetrazolium Violet (INT) overnight. Imaging and quantification were done using GelCount™ apparatus and associated software (Oxford Optronix, Abingdon, UK). Immunoblotting analysis, Co-immunoprecipitation (co-IP) and activate GTPase Pull down.
Flow cytometry
Mammospheres
Immunoblotting assays were performed using standard protocol following protein extraction using RIPA buffer as described previously (6) . Antibodies used in this paper include 
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